US Patent

US8003819 — Proteasome inhibitors

Method of Use · Assigned to Millennium Pharmaceuticals Inc · Expires 2027-08-06 · 1y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel compounds useful as proteasome inhibitors and methods of using them in the treatment of various diseases.

USPTO Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2434 — ixazomib-citrate
U-2434 — ixazomib-citrate
U-2434 — ixazomib-citrate

Patent Metadata

Patent number
US8003819
Jurisdiction
US
Classification
Method of Use
Expires
2027-08-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Millennium Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.